N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nykode Therapeutics ASA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Interest Income Expense
$11m
CAGR 3-Years
140%
CAGR 5-Years
178%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Interest Income Expense
-kr7.2m
CAGR 3-Years
2%
CAGR 5-Years
-20%
CAGR 10-Years
-10%
B
Bergenbio ASA
OSE:BGBIO
Interest Income Expense
kr9m
CAGR 3-Years
26%
CAGR 5-Years
21%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Interest Income Expense
kr8.9m
CAGR 3-Years
143%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Interest Income Expense
kr9.6m
CAGR 3-Years
593%
CAGR 5-Years
199%
CAGR 10-Years
22%
T
Thor Medical ASA
OSE:TRMED
Interest Income Expense
kr1.6m
CAGR 3-Years
N/A
CAGR 5-Years
-29%
CAGR 10-Years
-3%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Interest Income Expense?
Interest Income Expense
11m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Interest Income Expense amounts to 11m USD.

What is Nykode Therapeutics ASA's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
178%

Over the last year, the Interest Income Expense growth was 54%. The average annual Interest Income Expense growth rates for Nykode Therapeutics ASA have been 140% over the past three years , 178% over the past five years .

Back to Top